Last month I was invited to join a pre-ASH group of multiple myeloma patients who were experiencing peripheral neuropathy (PN). I wanted to share my notes and thoughts about the almost three hour round table event with you.
The gathering was called the International Myeloma Foundation Peripheral Neuropathy Patient Focus Group.
Our facilitators were oncology nurses Teresa Miceli from the Mayo Clinic and Tiffany Richards with MD Anderson in Houston.
The round table featured a group of 12 multiple myeloma survivors who all shared one thing in common: symptomatic peripheral neuropathy. Fifteen or so caregivers and IMF officials–including IMF President Suzie Novis and event organizer Joanie Borbelly–attended the focus group as well.
Medical privacy issues prevent me from sharing the other patient’s names with you. The group consisted of five women and seven men, ages fifty years old and up.
These symptoms–as shared by the twelve participants–include numbness in the hands and feet, loss of balance, trouble writing, opening jars, trouble with buttons or zippers and/or pain in various parts of the body.
Teresa pointed-out and discussed several additional, serious conditions related to PN: low blood pressure and chronic diarrhea.
I soon learned most of the panel began to experience PN soon after beginning their treatments.
“Chemo brain” was also attributed, at least partially, to PN.
Most patients experienced at least some improvement after stopping treatment.
Five members of the group had undergone autologous stem cell transplants (SCT). No one experienced more PN symptoms than pre-transplant. However, Teresa mentioned it is not uncommon for PN to become more painful after SCT.
Three or four group members experienced PN prior to treatment.
PN assessments are an important part of monitoring a patient’s progress, yet many of the patients had never participated in a formal assessment.
Group participants and facilitators agreed a more systematic monitoring system might be helpful outside a clinical trial setting where formal assessment is more common.
Some patients shared that, as a result of PN, their treatments had been modified or stopped. Others had not experienced that.
The group enthusiastically provided input about what made our symptoms worse. Cold, poor fitting shoes and standing for long periods of time topped the list. Several mentioned their PN was worse at night.
As far as suggestions which improve PN, gabapenten was most often mentioned. Vitamin B and alpha lipoic acid were also used by a majority of patients.
Both nurses mentioned Cybalta might help. No one in the group was using this drug–partially because insurance often doesn’t pay for Cybalta or Lyrica for PN unless it is related to diabetes.
Alternative treatments mentioned included massage and acupuncture. Another group member mentioned cocoa butter helped. I mentioned using topical magnesium might also help, especially for cramping.
Kataline and Amitriptyline can be effective numbing painful neuropathy when applied to the feet after soaking them in warm water. Teresa and Tiffany noted this combination may not be available everywhere and would require a prescription.
Safety (slipping in the shower, checking water temperature before bathing, injury doing simple things like trimming toe nails and falling) were mentioned as concerns.
Both nurses reminded us how important it is to maintain a relationship with a primary care physician–and that they are aware of your PN and symptoms.
Patient to patient sharing can also be a helpful way to learn more about what works and doesn’t work for other patients.
Two fun observations: The men sure talked more than the women–probably no surprise for my female readers!
Also, sex and sexual function was also discussed. Like an unruly junior high school class, there was lots of joking and side discussions going on during this part of the program. But kidding aside, it soon became clear that sexual dysfunction–especially among the men–was apparent.
I felt this round table workshop was very worthwhile. The IMF is to be commended for giving patients an opportunity to get together and discuss their experiences with each other.
But more important than that, the IMF is collecting data from these meetings to help improve guidelines for patient care.
I’m not easily impressed, but this was a great idea–and well worth giving-up a sunny Florida afternoon to help-out.
Don’t forget, starting tomorrow I will be posting multiple myeloma related articles from here in Orlando at least twice daily through Tuesday.
I’m excited about the opportunity. Feel good and keep smiling! Pat